A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease
Evaluation of Homogeneity Between eGFR Slopes Derived From Retrospective Clinical Practice Data and eGFR Slopes Derived From Prospectively Collected, Protocol-driven Data
Sponsor: Boehringer Ingelheim
Terminated
Recruitment challenges
Other terminated trials from Boehringer Ingelheim
Other Chronic Kidney Disease trials with similar outcome
A PHASE2 clinical study on Chronic Kidney Disease, this trial is terminated or withdrawn. The trial is conducted by Boehringer Ingelheim and has accumulated 17 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Sep 2023 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 12 earlier versions
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting · Phase: NA → PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting NA
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting NA
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .